An Astrocytic Influence on Impaired Tonic Inhibition in Hippocampal CA1 Pyramidal Neurons in a Mouse Model of Rett...

Area of Science:

• Neuroscience
• Neurodevelopmental disorders
• Molecular biology

Background:

• Rett syndrome (RTT) is a severe neurodevelopmental disorder caused by mutations in the methyl-CpG binding protein 2 (MECP2) gene.
• While altered interneuron function is known in RTT, tonic inhibition has not been thoroughly investigated.

Purpose of the Study:

• To examine tonic inhibition in the hippocampus of Mecp2-deficient mice.
• To investigate the role of astrocytes and GABA transporters in RTT-associated neuronal dysfunction.
• To evaluate GAT3 antagonism as a potential therapeutic strategy for RTT.

Main Methods:

• Electrophysiological recordings in CA1 pyramidal neurons of Mecp2 knockout mice.
• Assessment of GABA receptor levels and GABA transporter 3 (GAT3) expression and function.
• Pharmacological manipulation of GAT3 activity in acute brain slices and in vivo.
• Evaluation of behavioral and survival outcomes in treated Mecp2 knockout mice.

Main Results:

• Tonic inhibition was significantly reduced in CA1 pyramidal neurons of Mecp2 knockout mice.
• This reduction correlated with increased GAT3 expression and activity in hippocampal astrocytes, not altered GABA receptors.
• Pharmacological blockade of GAT3 normalized tonic inhibition and neuronal excitability.
• Chronic GAT3 antagonist administration improved RTT mouse symptoms and extended lifespan.

Conclusions:

• Reduced tonic inhibition, mediated by astrocytic GAT3 upregulation, is a novel phenotype in RTT.
• Targeting astrocytic GAT3 offers a promising therapeutic avenue for Rett syndrome.
• This study highlights the crucial role of astrocyte-glia interactions in neurodevelopmental disorders.